Boston Scientific Reduces 2026 Sales and Earnings Guidance
Boston Scientific has reduced its 2026 sales and earnings guidance due to challenges in key business areas such as electrophysiology and the Watchman franchise. The company now expects full-year sales growth of 7% to 8.5%, down from 10.5% to 11.5%, and adjusted earnings per share of $3.34 to $3.41, down from $3.43 to $3.49. The guidance cut reflects declining Watchman volume and other operational challenges.
Tickers: $BSX
Topics: Boston Scientific Earnings Electrophysiology Guidance Sales Growth Urology Watchman